Artivion 

€28.95
31
-€2.7-8.53% Today

Statistics

Day High
32.8
Day Low
32.8
52W High
41.1
52W Low
19.44
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Dec 15
€0.03
Sep 15
€0.03
Jun 15
€0.03
Mar 15
€0.03
Dec 14
€0.02
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

30AprExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.39
-0.22
-0.04
0.13
Expected EPS
0.028571
Actual EPS
N/A

Financials

2.19%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
758.93MRevenue
16.61MNet Income

Analyst Ratings

$39.08Average Price Target
The highest estimate is 44.01.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CYL.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Medtronic
MDT
Mkt Cap116.33B
Medtronic is a major player in the medical devices sector, offering products that compete directly with Artivion's cardiovascular and neurosurgical devices.
Boston Scientific
BSX
Mkt Cap149.24B
Boston Scientific competes in the cardiovascular market, offering a range of products that overlap with Artivion's offerings.
Edwards Lifesciences
EW
Mkt Cap48.41B
Edwards Lifesciences specializes in heart valves and hemodynamic monitoring, directly competing with Artivion's cardiovascular solutions.
Abbott Laboratories
ABT
Mkt Cap214.96B
Abbott Laboratories offers medical devices, including cardiovascular and neuromodulation products, that compete with Artivion's portfolio.
Stryker
SYK
Mkt Cap136.19B
Stryker operates in the medical technology field, offering products that compete with Artivion's surgical solutions and medical devices.
Zimmer Biomet
ZBH
Mkt Cap19.92B
Zimmer Biomet Holdings, Inc. competes in the musculoskeletal healthcare sector, which can overlap with some of Artivion's surgical device offerings.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson's medical devices segment offers a broad range of products that compete across several of Artivion's key areas, including surgery and cardiovascular health.
Intuitive Surgical
ISRG
Mkt Cap189.4B
Intuitive Surgical specializes in robotic-assisted surgery, competing with Artivion's surgical devices and technologies.
Baxter International
BAX
Mkt Cap9.49B
Baxter International Inc. provides a broad array of medical devices and services that can compete with Artivion's offerings in the healthcare sector.
Integra Lifesciences
IART
Mkt Cap935.48M
Integra LifeSciences offers products in neurosurgery, reconstructive and general surgery, directly competing with some of Artivion's surgical and medical device solutions.

About

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac and preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts, including E-vita Open NEO, E-vita Open Plus, ascyrus medical dissection stent hybrid prosthesis, E-vita THORACIC 3G products, and NEXUS products. It also offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries and aneurysmal iliac side branches; Tuva BX, a balloon-expandable peripheral stent graft to treat arterial ruptures, aneurysms, and other peripheral vascular system pathologies; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves, and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures for mitral chordal replacement; and pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
Show more...
CEO
Mr. James Patrick Mackin
Employees
1600
Country
US
ISIN
US2289031005
WKN
000900006

Listings

0 Comments

Share your thoughts

FAQ

What is Artivion stock price today?
The current price of CYL.F is €28.95 EUR — it has decreased by -8.53% in the past 24 hours. Watch Artivion stock price performance more closely on the chart.
What is Artivion stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Artivion stocks are traded under the ticker CYL.F.
Is Artivion stock price growing?
CYL.F stock has fallen by -6.16% compared to the previous week, the month change is a -9.39% fall, over the last year Artivion has showed a +27.25% increase.
When is the next Artivion earnings date?
Artivion is going to release the next earnings report on April 30, 2026.
What were Artivion earnings last quarter?
CYL.F earnings for the last quarter are 0.04 EUR per share, whereas the estimation was 0.05 EUR resulting in a -10.71% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Artivion revenue for the last year?
Artivion revenue for the last year amounts to 758.93M EUR.
What is Artivion net income for the last year?
CYL.F net income for the last year is 16.61M EUR.
Does Artivion pay dividends?
Yes, CYL.F dividends are paid quarterly. The last dividend per share was 0.03 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Artivion have?
As of April 02, 2026, the company has 1,600 employees.
In which sector is Artivion located?
Artivion operates in the Health Care sector.
When did Artivion complete a stock split?
Artivion has not had any recent stock splits.
Where is Artivion headquartered?
Artivion is headquartered in Kennesaw, US.